VPPM Performance — ProFund VP Pharmaceuticals
Data updated: 2026-08-28
VPPM returned +17.80% year to date and +62.19% over one year to Jun 2026. Annualised returns are +16.88% over 3 years and +8.49% over 5 years. The fund beat its Health Care Equity category average: $100 invested three years ago grew to $160, against $138 for the category, and to $162 over one year, against $137. Volatility over the past three years was 20.76% a year. In the 12 months to Jun 2026 the fund took in a net $773K, and assets reached $11.52M.
VPPM Growth of $100
What $100 invested in ProFund VP Pharmaceuticals grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Health Care Equity category average over the same months.
| Period | VPPM | Category average |
|---|---|---|
| 1 year (Jul 2025 – Jun 2026) | $162 | $137 |
| 3 years (Jul 2023 – Jun 2026) | $160 | $138 |
| 5 years (Jul 2021 – Jun 2026) | $150 | $121 |
| Since data start (Jul 2019 – Jun 2026) | $186 | $182 |
VPPM Trailing Returns
Total returns to Jun 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +17.80% |
| 1 year | +62.19% |
| 3 years (annualised) | +16.88% |
| 5 years (annualised) | +8.49% |
VPPM Annual Returns
Calendar-year total returns of ProFund VP Pharmaceuticals, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jun) | +17.80% |
| 2025 | +29.34% |
| 2024 | +3.41% |
| 2023 | −5.50% |
| 2022 | −6.14% |
| 2021 | +11.20% |
| 2020 | +12.52% |
| 2019 (Jul–Dec) | +6.28% |
VPPM Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | −1.5% | +3.6% | −6.0% | +6.7% | +1.0% | +13.9% | — | — | — | — | — | — |
| 2025 | +4.7% | −1.3% | −1.4% | −6.0% | −1.7% | −0.1% | +1.6% | +14.7% | +1.2% | +3.5% | +10.0% | +2.6% |
| 2024 | +0.9% | +5.7% | −2.7% | −7.8% | +1.5% | −1.2% | +8.6% | +3.1% | −0.5% | +3.6% | +0.1% | −6.7% |
| 2023 | −0.5% | −5.3% | −1.0% | +2.4% | −6.3% | +4.2% | +6.4% | −0.1% | −8.9% | −10.0% | +3.1% | +12.8% |
| 2022 | −4.6% | −3.7% | +6.0% | −3.4% | +3.4% | −1.1% | −0.8% | −7.7% | −3.4% | +6.8% | +3.6% | −0.3% |
| 2021 | −0.1% | −0.8% | −0.5% | +0.9% | +2.8% | +0.9% | +3.2% | +0.6% | −5.0% | +2.7% | −0.7% | +6.9% |
| 2020 | −0.5% | −9.3% | −6.4% | +12.8% | +3.2% | −2.1% | +2.5% | +5.9% | −2.1% | −2.4% | +7.1% | +5.2% |
| 2019 | — | — | — | — | — | — | −4.3% | −3.6% | +0.5% | +4.3% | +3.4% | +6.2% |
VPPM Risk
Risk measures from monthly returns over Jul 2023 – Jun 2026.
- 3-year volatility (annualised): 20.76%
- 3-year Sharpe ratio: 0.60 (vs 4.5% risk-free rate)
- Best month: +14.68% (Aug 2025)
- Worst month: −10.02% (Oct 2023)
VPPM Fund Flows
Monthly money in and out of ProFund VP Pharmaceuticals, from SEC Form N-PORT.
- 12-month net flow: $773K
- 12-month gross sales (incl. reinvestments): $17.5M
- Sales ÷ redemptions: 1.05×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jun 2026 | $2.1M | $408K | $1.7M |
| May 2026 | $309K | $203K | $106K |
| Apr 2026 | $427K | $1.4M | −$990K |
| Mar 2026 | $1.5M | $1.5M | −$4K |
| Feb 2026 | $315K | $286K | $29K |
| Jan 2026 | $1.6M | $1.5M | $77K |
| Dec 2025 | $2.0M | $2.6M | −$595K |
| Nov 2025 | $1.5M | $799K | $686K |
| Oct 2025 | $3.8M | $4.2M | −$403K |
| Sep 2025 | $1.2M | $1.8M | −$573K |
| Aug 2025 | $1.8M | $1.2M | $583K |
| Jul 2025 | $1.0M | $888K | $153K |
VPPM Assets Under Management
Net assets of ProFund VP Pharmaceuticals by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-06-30 | $11.52M |
| 2026-03-31 | $10.17M |
| 2025-12-31 | $10.49M |
| 2025-09-30 | $9.27M |
| 2025-06-30 | $7.69M |
| 2025-03-31 | $8.80M |
| 2024-12-31 | $9.36M |
| 2024-09-30 | $10.42M |
| 2024-06-30 | $9.44M |
| 2024-03-31 | $10.99M |
| 2023-12-31 | $10.36M |
| 2023-09-30 | $10.53M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.